The Life Sciences team advised Rubius Therapeutics on the closing of its initial public offering of 12,055,450 shares of common stock at a public offering price of $23.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,572,450 additional shares of common stock. The gross proceeds from the offering were approximately $277.3 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Rubius Therapeutics is pioneering the development of a new class of medicines, Red Cell Therapeutics, or RCTs. Rubius has designed a proprietary platform to genetically engineer and culture RCTs that are selective, potent and ready-to-use cellular therapies. Rubius raised the most money ever in an initial public offering by a biotechnology company in Massachusetts.